SAN DIEGO, CA--(Marketwired - Apr 27, 2015) - Spokespersons for Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) commented today regarding significant milestones presented by the Company at the 2015 American Association for Cancer Research Annual Meeting (AACR) as well as potential partnering opportunities that resulted from its presence at the event
Dr. Christine Ichim, Director of Molecular Therapeutics at Regen BioPharma Inc. stated, "Among the milestones presented by Regen BioPharma at the AACR Conference include assay development and hit identification as they pertain to the cancer stem cell target NR2F6. Hit identification is a process where a molecule is found to bind to a target. Drug discovery is akin to searching for a key to fit a lock. We have identified a drug shape that is able to bind to and inhibit the function of NR2F6. These are significant milestones because it narrows the number of possible small molecule shapes from an infinite number to a finite number. We have essentially found a template (which needs to be refined) to make the small molecule chemical more potent, less toxic and more drug-like, which will allow us to create a therapy for cancer treatment."
A Regen spokesperson stated the Company's next step is to refine the hit to develop a lead compound that can be tested pre-clinically for potential use in future clinical trials.
Regen BioPharma's Chairman & CEO David Koos noted "There was significant of interest paid to Regen's presentation at the AACR conference. I see abundant possible collaborations including co-development of related research areas. The Company received substantial interest with regards to both near term and longer term alliances in the areas of cancer stem cell and small molecule drug development. Gene Silencing was also an area receiving strong interest among researchers. Additionally, there are numerous in-licensing arrangements that could benefit Regen in its delivery systems for siRNA."
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.